Answers are grounded in this paper and cite their sources.
Immune thrombocytopenia with antiphospholipid syndrome and monoclonal gammopathy of undetermined significance poses therapeutic dilemmas – whether we should modify the immune thrombocytopenia treatment in antiphospholipid syndrome, what is the influence of monoclonal gammopathy of undetermined significance on the course of immune thrombocytopenia and whether we should and how to prevent the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
No takes yet. Share an insight, caveat, or question.
Ryżewska et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: